Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198980 | 0.94 | IRAK4 (0.45) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2198791 | 0.91 | KMT2A (0.44) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2198785 | 0.82 | POLB (0.52) | POLBKMT2AMEN1CYP1A2 | |
| SCHEMBL2198771 | 0.82 | KMT2A (0.44) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2201747 | 0.81 | KMT2A (0.47) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2200782 | 0.81 | IRAK4 (0.44) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2201429 | 0.81 | KMT2A (0.46) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2201156 | 0.79 | KMT2A (0.45) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2201495 | 0.78 | KMT2A (0.44) | IRAK4POLBKMT2AMEN1L3MBTL3 | |
| SCHEMBL2203232 | 0.76 | ALDH1A1 (0.46) | IRAK4POLBKMT2AMEN1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | IRAK4 146/4885POLB 4350/4885KMT2A 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.